Eli Lilly and Co to Provide an Overview of Tirzepatide Phase 3 Clinical Program - Conference Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : First, are there any obvious differences in physically where the SURPASS studies are happening versus SUSTAIN? Do studies tend to do one or the other? Or is there sort of mixing? And then looking ahead to obesity, hopefully. Mike, what have payers told you about their willingness to cover a product like tirzepatide for obese patients that do not have diabetes? I realize it's a ways out, but I'm sure you've asked the question and thought about it.

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Just 1 left for me, please. A broader question on costs in promotion in diabetes. So your competitor, Novo Nordisk recently confirmed it's reducing its U.S. sales force by around 25% and shifting those marketing costs through to digital routes. I wonder, is that a similar trend that Lilly is pursuing here within diabetes, specifically, more digital, less face-to-face promotion? And is that something that we can expect to continue? Could this ultimately result in lower selling costs going forward?